ERBB2 and breast carcinoma: In fact, overexpression c-Met has emerged as a potential contributor to trastuzumab resistance and has been shown to be highly elevated in HER2-positive breast cancer cell lines and in 25% of HER2-positive breast cancer patients tissues.[62, 65] Loss of Met function is implicated in the development of trastuzumab response.[65]